A PD Solution to Protect Peritoneal Membranes
PD-protec® by Zytoprotec, which now has FDA orphan drug status, is in Phase III trials among 300 patients in the US and Europe. The product aims to reduce PD complications such as peritonitis and membrane failure.
Read the full article » | Posted 01-11-2018
Related Articles
- Xeltis is Trialing its Polymer-based Vascular Access Posted 03-12-2026
- New Bluetooth-enabled CAPD System Enhanced Patient Satisfaction Posted 03-12-2026
- Emerging Biomarker Research in PD Posted 03-12-2026
- Byonyks’ X1 APD Cycler Received FDA 510(k) Approval Last Summer Posted 02-17-2026

